Published in JAMA on March 04, 2009
Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA (2009) 6.80
Proton Pump Inhibitor Usage and the Risk of Myocardial Infarction in the General Population. PLoS One (2015) 3.46
Unexpected effect of proton pump inhibitors: elevation of the cardiovascular risk factor asymmetric dimethylarginine. Circulation (2013) 3.45
Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome. Circulation (2009) 3.09
Outcomes with concurrent use of clopidogrel and proton-pump inhibitors: a cohort study. Ann Intern Med (2010) 2.90
Clopidogrel and interaction with proton pump inhibitors: comparison between cohort and within person study designs. BMJ (2012) 2.88
Drug interactions--principles, examples and clinical consequences. Dtsch Arztebl Int (2012) 2.02
Antiplatelet therapies for the treatment of cardiovascular disease. Nat Rev Drug Discov (2010) 1.66
Individual Proton Pump Inhibitors and Outcomes in Patients With Coronary Artery Disease on Dual Antiplatelet Therapy: A Systematic Review. J Am Heart Assoc (2015) 1.53
Risk score to predict serious bleeding in stable outpatients with or at risk of atherothrombosis. Eur Heart J (2010) 1.53
The Indications, Applications, and Risks of Proton Pump Inhibitors. Dtsch Arztebl Int (2016) 1.45
Adverse effects of long-term proton pump inhibitor therapy. Dig Dis Sci (2011) 1.43
Overutilization of proton-pump inhibitors: what the clinician needs to know. Therap Adv Gastroenterol (2012) 1.43
Privacy-maintaining propensity score-based pooling of multiple databases applied to a study of biologics. Med Care (2010) 1.25
PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 19. Pharmacogenet Genomics (2012) 1.25
Recent advances in antithrombotic therapy after acute coronary syndrome. CMAJ (2013) 1.23
Helicobacter pylori and gastroduodenal ulcer disease. Dtsch Arztebl Int (2009) 1.07
Diagnosis and management of nonvariceal upper gastrointestinal bleeding. Nat Rev Gastroenterol Hepatol (2012) 1.06
Pharmacokinetic drug interaction profiles of proton pump inhibitors: an update. Drug Saf (2014) 1.05
Clopidogrel pathway. Pharmacogenet Genomics (2010) 0.99
Influences of different proton pump inhibitors on the anti-platelet function of clopidogrel in relation to CYP2C19 genotypes. Br J Clin Pharmacol (2010) 0.98
Insights into the future of gastric acid suppression. Nat Rev Gastroenterol Hepatol (2009) 0.98
Impact of proton pump inhibitor therapy on the efficacy of clopidogrel in the CAPRIE and CREDO trials. J Am Heart Assoc (2013) 0.97
Trends in the coprescription of proton pump inhibitors with clopidogrel: an ecological analysis. CMAJ Open (2015) 0.95
The impact of treatment with omeprazole on the effectiveness of clopidogrel drug therapy during the first year after successful coronary stenting. Can J Cardiol (2010) 0.95
The risks of PPI therapy. Nat Rev Gastroenterol Hepatol (2012) 0.94
Risk of adverse clinical outcomes with concomitant use of clopidogrel and proton pump inhibitors following percutaneous coronary intervention. Dig Dis Sci (2010) 0.94
Current perspectives in NSAID-induced gastropathy. Mediators Inflamm (2013) 0.91
Appropriateness of treatment recommendations for PPI in hospital discharge letters. Eur J Clin Pharmacol (2010) 0.91
High residual platelet reactivity on clopidogrel: its significance and therapeutic challenges overcoming clopidogrel resistance. Cardiovasc Diagn Ther (2013) 0.91
Acetylsalicylic acid use in patients with acute myocardial infarction and peptic ulcer bleeding. Can J Gastroenterol (2009) 0.91
Association between proton pump inhibitor use and anemia: a retrospective cohort study. Dig Dis Sci (2011) 0.91
Personalized approaches to clopidogrel therapy: are we there yet? Stroke (2010) 0.90
Aspirin and clopidogrel hyporesponsiveness and nonresponsiveness in patients with coronary artery stenting. Vasc Health Risk Manag (2009) 0.90
Prasugrel. Nat Rev Drug Discov (2009) 0.90
Effects of drug interactions on biotransformation and antiplatelet effect of clopidogrel in vitro. Br J Pharmacol (2010) 0.90
Overcoming 'resistance' to antiplatelet therapy: targeting the issue of nonadherence. Nat Rev Cardiol (2010) 0.89
An automated tool for detecting medication overuse based on the electronic health records. Pharmacoepidemiol Drug Saf (2012) 0.88
Dual antiplatelet therapy in patients requiring urgent coronary artery bypass grafting surgery: a position statement of the Canadian Cardiovascular Society. Can J Cardiol (2009) 0.88
Interaction between clopidogrel and proton-pump inhibitors and management strategies in patients with cardiovascular diseases. Drug Healthc Patient Saf (2010) 0.88
Determinants to optimize response to clopidogrel in acute coronary syndrome. Pharmgenomics Pers Med (2010) 0.87
Omeprazole induces gastric permeability to digoxin. Dig Dis Sci (2009) 0.87
Variability in response to clopidogrel: how important are pharmacogenetics and drug interactions? Br J Clin Pharmacol (2011) 0.87
Hotlines and clinical trial updates presented at the European Society of Cardiology Meeting 2009: data from RE-LY, PLATO, MADIT-CRT, PROTECT, SYNTAX, TRITON and more. Clin Res Cardiol (2009) 0.86
Clopidogrel and proton pump inhibitors--where do we stand in 2012? World J Gastroenterol (2012) 0.85
Proton pump inhibitors for prophylaxis of nosocomial upper gastrointestinal tract bleeding: effect of standardized guidelines on prescribing practice. Arch Intern Med (2010) 0.85
Feasibility of pharmacy-initiated pharmacogenetic screening for CYP2D6 and CYP2C19. Eur J Clin Pharmacol (2011) 0.85
Proton pump inhibitors in prevention of low-dose aspirin-associated upper gastrointestinal injuries. World J Gastroenterol (2015) 0.85
Adverse cardiovascular outcomes associated with concurrent use of clopidogrel or ticlopidine and proton-pump inhibitors in patients undergoing percutaneous coronary intervention. Heart Vessels (2012) 0.85
Antiplatelet resistance in stroke. Expert Rev Neurother (2011) 0.85
Effect of the clopidogrel-proton pump inhibitor drug interaction on adverse cardiovascular events in patients with acute coronary syndrome. Pharmacotherapy (2012) 0.84
Comparison of a basic and an advanced pharmacotherapy-related clinical decision support system in a hospital care setting in the Netherlands. J Am Med Inform Assoc (2011) 0.84
The potential interaction between clopidogrel and proton pump inhibitors: a systematic review. BMC Med (2010) 0.84
The safety of drugs used in acid-related disorders and functional gastrointestinal disorders. Gastroenterol Clin North Am (2010) 0.83
Proton pump inhibitors and vascular function: A prospective cross-over pilot study. Vasc Med (2015) 0.83
Gastric ulcer healing after treatment of endoscopic submucosal dissection in Japanese: comparison of H(2) receptor antagonist and proton pump inhibitor administration. J Clin Biochem Nutr (2011) 0.83
Incidence of cardiovascular events and gastrointestinal bleeding in patients receiving clopidogrel with and without proton pump inhibitors: an updated meta-analysis. Open Heart (2015) 0.83
Responding to the clopidogrel warning by the US food and drug administration: real life is complicated. Circulation (2010) 0.83
Proton pump inhibitors and risk of vitamin and mineral deficiency: evidence and clinical implications. Ther Adv Drug Saf (2013) 0.83
Gaviscon® vs. omeprazole in symptomatic treatment of moderate gastroesophageal reflux. a direct comparative randomised trial. BMC Gastroenterol (2012) 0.82
Cardiovascular and gastrointestinal events of three antiplatelet therapies: clopidogrel, clopidogrel plus proton-pump inhibitors, and aspirin plus proton-pump inhibitors in patients with previous gastrointestinal bleeding. J Gastroenterol (2010) 0.82
Diagnosis and therapy of non-variceal upper gastrointestinal bleeding. World J Gastrointest Pharmacol Ther (2015) 0.82
Clopidogrel and proton pump inhibitor (PPI) interaction: separate intake and a non-omeprazole PPI the solution? Eur J Med Res (2010) 0.81
Adverse outcomes associated with use of proton pump inhibitors and clopidogrel. JAMA (2009) 0.81
Adverse outcomes associated with use of proton pump inhibitors and clopidogrel. JAMA (2009) 0.81
Potential savings of harmonising hospital and community formularies for chronic disease medications initiated in hospital. PLoS One (2012) 0.80
Esomeprazole and aspirin fixed combination for the prevention of cardiovascular events. Vasc Health Risk Manag (2013) 0.80
Prevention of stress-related ulcer bleeding at the intensive care unit: Risks and benefits of stress ulcer prophylaxis. World J Crit Care Med (2016) 0.80
Contemporary treatment of unstable angina and non-ST-segment-elevation myocardial infarction (part 2). Tex Heart Inst J (2010) 0.80
Two-week treatment with proton pump inhibitor is sufficient for healing post endoscopic submucosal dissection ulcers. World J Gastroenterol (2014) 0.79
Vertebral fracture efficacy during risedronate therapy in patients using proton pump inhibitors. Osteoporos Int (2011) 0.79
Impact of dual antiplatelet therapy with proton pump inhibitors on the outcome of patients with acute coronary syndrome undergoing drug-eluting stent implantation. ISRN Cardiol (2012) 0.79
Clinical evidence of interaction between clopidogrel and proton pump inhibitors. World J Cardiol (2011) 0.79
Prognosis of concomitant users of clopidogrel and proton-pump inhibitors in a high-risk population for upper gastrointestinal bleeding. BMC Pharmacol Toxicol (2014) 0.78
Effects of Clopidogrel and Proton Pump Inhibitors on Cardiovascular Events in Patients with Type 2 Diabetes Mellitus after Drug-Eluting Stent Implantation: A Nationwide Cohort Study. PLoS One (2015) 0.78
Increased risk for developing major adverse cardiovascular events in stented Chinese patients treated with dual antiplatelet therapy after concomitant use of the proton pump inhibitor. PLoS One (2014) 0.78
Proton pump inhibitors and clopidogrel - hazardous drug interaction or hazardous interpretation of data? Can J Gastroenterol (2009) 0.78
Inappropriate use of proton pump inhibitors among medical inpatients: a questionnaire-based observational study. JRSM Short Rep (2013) 0.78
Clinical relevance of clopidogrel-proton pump inhibitors interaction. World J Gastrointest Pharmacol Ther (2015) 0.78
[PPI for dual therapy with clopidogrel: to use or not to use? ]. Z Gastroenterol (2010) 0.78
The promises of personalized medicine. Eur J Clin Pharmacol (2010) 0.78
Cardiovascular outcomes associated with concomitant use of clopidogrel and proton pump inhibitors in patients with acute coronary syndrome in Taiwan. Br J Clin Pharmacol (2012) 0.78
Evaluation of Aspirin and Clopidogrel resistance in patients with Acute Coronary Syndrome by using Adenosine Diposphate Test and Aspirin Test. Pak J Med Sci (2013) 0.77
Antiplatelet agents and proton pump inhibitors - personalizing treatment. Pharmgenomics Pers Med (2010) 0.77
How May Proton Pump Inhibitors Impair Cardiovascular Health? Am J Cardiovasc Drugs (2016) 0.77
Clostridium difficile infection in the community: are proton pump inhibitors to blame? World J Gastroenterol (2013) 0.77
Nonsteroidal Anti-Inflammatory Drug-Induced Gastroduodenal Bleeding: Risk Factors and Prevention Strategies. Pharmaceuticals (Basel) (2010) 0.77
Modern role for clopidogrel in management of atrial fibrillation and stroke reduction. Vasc Health Risk Manag (2010) 0.77
The interaction between clopidogrel and proton pump inhibitors (PPI): is there any clinical relevance? Clin Pharmacol (2010) 0.77
Lack of significant interactions between clopidogrel and proton pump inhibitor therapy: meta-analysis of existing literature. Dig Dis Sci (2011) 0.77
Effect of proton pump inhibitors on platelet inhibition activity of clopidogrel in Chinese patients with percutaneous coronary intervention. Vasc Health Risk Manag (2011) 0.77
Topical nonsteroidal anti-inflammatory drugs for management of osteoarthritis in long-term care patients. Ther Clin Risk Manag (2011) 0.77
Drug-drug interaction of rabeprazole and clopidogrel in healthy Chinese volunteers. Eur J Clin Pharmacol (2012) 0.77
Cardiovascular effects of noncardiovascular drugs. Circulation (2009) 0.76
Omeprazole, pantoprazole, and CYP2C19 effects on clopidogrel pharmacokinetic-pharmacodynamic relationships in stable coronary artery disease patients. Eur J Clin Pharmacol (2015) 0.76
Does laryngopharyngeal reflux cause intraoral burning sensations? A preliminary study. Eur Arch Otorhinolaryngol (2011) 0.76
Impact of proton pump inhibitors on efficacy of clopidogrel: Review of evidence. Indian J Pharmacol (2011) 0.76
Challenges in pharmacogenetics. Eur J Clin Pharmacol (2013) 0.76
Effects of proton pump inhibitors on lung cancer precise radiotherapy-induced radiation pneumonitis. Cell Biochem Biophys (2014) 0.76
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature (2012) 31.78
Mapping and analysis of chromatin state dynamics in nine human cell types. Nature (2011) 24.37
Efficient design and assembly of custom TALEN and other TAL effector-based constructs for DNA targeting. Nucleic Acids Res (2011) 16.53
Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA (2013) 12.37
Ethical and scientific implications of the globalization of clinical research. N Engl J Med (2009) 11.42
Prevalence of chronic kidney disease in China: a cross-sectional survey. Lancet (2012) 10.53
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med (2015) 9.70
Low diagnostic yield of elective coronary angiography. N Engl J Med (2010) 9.38
The genome of the mesopolyploid crop species Brassica rapa. Nat Genet (2011) 8.23
Application of new cholesterol guidelines to a population-based sample. N Engl J Med (2014) 8.22
Door-to-balloon time and mortality among patients undergoing primary PCI. N Engl J Med (2013) 8.08
Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA (2006) 7.81
Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. Arch Intern Med (2006) 7.54
Exercise is associated with reduced risk for incident dementia among persons 65 years of age and older. Ann Intern Med (2006) 7.14
Depressive symptoms and health-related quality of life: the Heart and Soul Study. JAMA (2003) 7.01
Relationship between early physician follow-up and 30-day readmission among Medicare beneficiaries hospitalized for heart failure. JAMA (2010) 6.91
Does this woman have an acute uncomplicated urinary tract infection? JAMA (2002) 5.74
Survival after initial diagnosis of Alzheimer disease. Ann Intern Med (2004) 5.52
Comparative effectiveness of revascularization strategies. N Engl J Med (2012) 5.49
Medication adherence: its importance in cardiovascular outcomes. Circulation (2009) 5.30
Endoscopic versus open vein-graft harvesting in coronary-artery bypass surgery. N Engl J Med (2009) 5.19
Time to treatment with intravenous tissue plasminogen activator and outcome from acute ischemic stroke. JAMA (2013) 5.05
Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circ Heart Fail (2013) 4.98
Sex and racial differences in the use of implantable cardioverter-defibrillators among patients hospitalized with heart failure. JAMA (2007) 4.89
Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. J Clin Invest (2004) 4.65
2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2014) 4.57
ACCF 2012 expert consensus document on practical clinical considerations in the interpretation of troponin elevations: a report of the American College of Cardiology Foundation task force on Clinical Expert Consensus Documents. J Am Coll Cardiol (2012) 4.45
Impact of medication therapy discontinuation on mortality after myocardial infarction. Arch Intern Med (2006) 4.44
The Society of Thoracic Surgeons 2008 cardiac surgery risk models: part 1--coronary artery bypass grafting surgery. Ann Thorac Surg (2009) 4.39
Appropriateness of percutaneous coronary intervention. JAMA (2011) 4.33
Predicting mortality and healthcare utilization with a single question. Health Serv Res (2005) 4.19
Compliance with results reporting at ClinicalTrials.gov. N Engl J Med (2015) 4.17
Variation in use of blood transfusion in coronary artery bypass graft surgery. JAMA (2010) 4.13
Effect of door-to-balloon time on mortality in patients with ST-segment elevation myocardial infarction. J Am Coll Cardiol (2006) 4.11
Health status predicts long-term outcome in outpatients with coronary disease. Circulation (2002) 4.10
An empirically based tool for analyzing mortality associated with congenital heart surgery. J Thorac Cardiovasc Surg (2009) 4.10
Comparative epigenomic analysis of murine and human adipogenesis. Cell (2010) 4.08
Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome. JAMA (2008) 4.06
Brahma links the SWI/SNF chromatin-remodeling complex with MeCP2-dependent transcriptional silencing. Nat Genet (2005) 3.98
Risk of major adverse cardiac events following noncardiac surgery in patients with coronary stents. JAMA (2013) 3.88
Validation of European System for Cardiac Operative Risk Evaluation (EuroSCORE) in North American cardiac surgery. Eur J Cardiothorac Surg (2002) 3.86
Clinical and economic implications of the Multicenter Automatic Defibrillator Implantation Trial-II. Ann Intern Med (2005) 3.83
Pay for performance, quality of care, and outcomes in acute myocardial infarction. JAMA (2007) 3.79
Economic analysis of influenza vaccination and antiviral treatment for healthy working adults. Ann Intern Med (2002) 3.77
The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells. Proc Natl Acad Sci U S A (2005) 3.72
Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. JAMA (2005) 3.72
Conversion of cardiovascular conference abstracts to publications. Circulation (2012) 3.71
Importance of therapy intensification and medication nonadherence for blood pressure control in patients with coronary disease. Arch Intern Med (2008) 3.68
Association between stroke center hospitalization for acute ischemic stroke and mortality. JAMA (2011) 3.68
Association of age and sex with myocardial infarction symptom presentation and in-hospital mortality. JAMA (2012) 3.66
An updated definition of stroke for the 21st century: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke (2013) 3.60
Linking inpatient clinical registry data to Medicare claims data using indirect identifiers. Am Heart J (2009) 3.57
Comparative efficacy of dronedarone and amiodarone for the maintenance of sinus rhythm in patients with atrial fibrillation. J Am Coll Cardiol (2009) 3.54
Patient-specific induced pluripotent stem cells as a model for familial dilated cardiomyopathy. Sci Transl Med (2012) 3.53
Systematic dissection and optimization of inducible enhancers in human cells using a massively parallel reporter assay. Nat Biotechnol (2012) 3.52
Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. Circulation (2006) 3.45
Racial and ethnic differences in time to acute reperfusion therapy for patients hospitalized with myocardial infarction. JAMA (2004) 3.45
The Society of Thoracic Surgeons 2008 cardiac surgery risk models: part 2--isolated valve surgery. Ann Thorac Surg (2009) 3.45
Circulating microRNAs, miR-21, miR-122, and miR-223, in patients with hepatocellular carcinoma or chronic hepatitis. Mol Carcinog (2010) 3.44
Number of coronary heart disease risk factors and mortality in patients with first myocardial infarction. JAMA (2011) 3.44
Medication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery disease. Am Heart J (2008) 3.40
Bedside tool for predicting the risk of postoperative dialysis in patients undergoing cardiac surgery. Circulation (2006) 3.38
Timeliness of tissue-type plasminogen activator therapy in acute ischemic stroke: patient characteristics, hospital factors, and outcomes associated with door-to-needle times within 60 minutes. Circulation (2011) 3.30
Monitoring clinical changes in patients with heart failure: a comparison of methods. Am Heart J (2005) 3.26
The future of general internal medicine. Report and recommendations from the Society of General Internal Medicine (SGIM) Task Force on the Domain of General Internal Medicine. J Gen Intern Med (2004) 3.19
Association between physician billing and cardiac stress testing patterns following coronary revascularization. JAMA (2011) 3.19
Risks of intracranial hemorrhage among patients with acute ischemic stroke receiving warfarin and treated with intravenous tissue plasminogen activator. JAMA (2012) 3.07
Use of aldosterone antagonists in heart failure. JAMA (2009) 3.00
Long-term outcomes and costs of ventricular assist devices among Medicare beneficiaries. JAMA (2008) 2.96
Laparoscopic versus open appendectomy: outcomes comparison based on a large administrative database. Ann Surg (2004) 2.95
Complete genome sequence of Yersinia pestis strain 91001, an isolate avirulent to humans. DNA Res (2004) 2.95
A decade of change--risk profiles and outcomes for isolated coronary artery bypass grafting procedures, 1990-1999: a report from the STS National Database Committee and the Duke Clinical Research Institute. Society of Thoracic Surgeons. Ann Thorac Surg (2002) 2.91